» Articles » PMID: 37287969

Cognitive Impairment in Long-COVID and Its Association with Persistent Dysregulation in Inflammatory Markers

Abstract

Objective: To analyze the potential impact of sociodemographic, clinical and biological factors on the long-term cognitive outcome of patients who survived moderate and severe forms of COVID-19.

Methods: We assessed 710 adult participants (Mean age = 55 ± 14; 48.3% were female) 6 to 11 months after hospital discharge with a complete cognitive battery, as well as a psychiatric, clinical and laboratory evaluation. A large set of inferential statistical methods was used to predict potential variables associated with any long-term cognitive impairment, with a focus on a panel of 28 cytokines and other blood inflammatory and disease severity markers.

Results: Concerning the subjective assessment of cognitive performance, 36.1% reported a slightly poorer overall cognitive performance, and 14.6% reported being severely impacted, compared to their pre-COVID-19 status. Multivariate analysis found sex, age, ethnicity, education, comorbidity, frailty and physical activity associated with general cognition. A bivariate analysis found that G-CSF, IFN-alfa2, IL13, IL15, IL1.RA, EL1.alfa, IL45, IL5, IL6, IL7, TNF-Beta, VEGF, Follow-up C-Reactive Protein, and Follow-up D-Dimer were significantly (p<.05) associated with general cognition. However, a LASSO regression that included all follow-up variables, inflammatory markers and cytokines did not support these findings.

Conclusion: Though we identified several sociodemographic characteristics that might protect against cognitive impairment following SARS-CoV-2 infection, our data do not support a prominent role for clinical status (both during acute and long-stage of COVID-19) or inflammatory background (also during acute and long-stage of COVID-19) to explain the cognitive deficits that can follow COVID-19 infection.

Citing Articles

[Cognition and Long COVID: A PRISMA Systematic Review of Longitudinal Studies].

Tudorache Pantazi M, Gadea-Domenech M, Espert Tortajada R Rev Neurol. 2025; 79(12):37385.

PMID: 39910970 PMC: 11799851. DOI: 10.31083/RN37385.


Prevalence of depression, anxiety, stress, and suicide tendency among individual with long-COVID and determinants: A systematic review and meta-analysis.

Bidhendi-Yarandi R, Biglarian A, Karlstad J, Moe C, Bakhshi E, Khodaei-Ardakani M PLoS One. 2025; 20(1):e0312351.

PMID: 39874315 PMC: 11774403. DOI: 10.1371/journal.pone.0312351.


Clinical rationale for dietary lutein supplementation in long COVID and mRNA vaccine injury syndromes.

Kyriakopoulos A, Nigh G, McCullough P, Seneff S F1000Res. 2024; 13:191.

PMID: 39526116 PMC: 11549548. DOI: 10.12688/f1000research.143517.3.


Cluster analysis identifies long COVID subtypes in Belgian patients.

Mfouth Kemajou P, Besse-Hammer T, Lebouc C, Coppieters Y Biol Methods Protoc. 2024; 9(1):bpae076.

PMID: 39478809 PMC: 11522879. DOI: 10.1093/biomethods/bpae076.


Clinical usefulness of the serum levels of neuroinflammatory and lung fibrosis biomarkers in the assessment of cognitive dysfunction in post-COVID19 patients.

Kulczynska-Przybik A, Czupryna P, Adamczuk J, Kruszewska E, Mroczko B, Moniuszko-Malinowska A Sci Rep. 2024; 14(1):25798.

PMID: 39468309 PMC: 11519350. DOI: 10.1038/s41598-024-76630-4.


References
1.
Rubin L, Benning L, Keating S, Norris P, Burke-Miller J, Savarese A . Variability in C-reactive protein is associated with cognitive impairment in women living with and without HIV: a longitudinal study. J Neurovirol. 2017; 24(1):41-51. PMC: 6036635. DOI: 10.1007/s13365-017-0590-4. View

2.
Damiano R, Brandao Neto D, Oliveira J, Santos J, Alves J, Guedes B . Association between chemosensory impairment with neuropsychiatric morbidity in post-acute COVID-19 syndrome: results from a multidisciplinary cohort study. Eur Arch Psychiatry Clin Neurosci. 2022; 273(2):325-333. PMC: 9142732. DOI: 10.1007/s00406-022-01427-3. View

3.
Damiano R, Caruso M, Cincoto A, Castanho de Almeida Rocca C, de Padua Serafim A, Bacchi P . Post-COVID-19 psychiatric and cognitive morbidity: Preliminary findings from a Brazilian cohort study. Gen Hosp Psychiatry. 2022; 75:38-45. PMC: 8734055. DOI: 10.1016/j.genhosppsych.2022.01.002. View

4.
Langarizadeh M, Tavakoli M, Abiri A, Ghasempour A, Rezaei M, Ameri A . A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms. EXCLI J. 2021; 20:339-365. PMC: 7975631. DOI: 10.17179/excli2020-3196. View

5.
Solinas A, Piras M, Deplano A . Cognitive dysfunction and hepatitis C virus infection. World J Hepatol. 2015; 7(7):922-5. PMC: 4419096. DOI: 10.4254/wjh.v7.i7.922. View